Patent ID: 7592346

Claim:
A method of treatment of depression or anxiety in a human in need thereof which comprises administering to said human an effective amount of: a compound of formula (Ib), or a pharmaceutically acceptable salt thereof: wherein: R 1 is halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy or haloC 1-6 alkyl; X is N or CH; R 3 and R 4 are independently hydrogen, C 1-6 alkyl, C 1-6 alkylsulfonyl, a group having the formula (IIa): wherein A is oxygen or sulfur, D is —(CH 2 ) t —, —(CH 2 ) t O— or —O(CH 2 ) t —, wherein t is 0, 1, 2, 3 or 4; and E is C 1-6 alkyl; C 3-7 cycloalkyl, optionally substituted by one or more substituents independently selected from halogen, hydroxy, oxo, C 1-6 alkyl, cyano, CF 3 , OCF 3 , C 1-6 alkoxy and C 1-6 alkanoyl; or aryl, optionally substituted by one or more substituents independently selected from halogen, C 1-6 alkyl, CF 3 , cyano, hydroxy, C 1-6 alkanoyl, and C 1-6 alkoxy; or a group having the formula (IIb) wherein A is oxygen or sulfur, D is —(CH 2 ) t —, —(CH 2 ) t O— or —O(CH 2 ) t —, wherein t is 0, 1, 2, 3 or 4; and E is C 1-6 alkyl; C 3-7 cycloalkyl, optionally substituted by one or more substituents independently selected from halogen, hydroxy, oxo, C 1-6 alkyl, cyano, CF 3 , OCF 3 , C 1-6 alkoxy and C 1-6 alkanoyl; or aryl optionally substituted by one or more substituents independently selected from halogen, C 1-6 alkyl, CF 3 , cyano, hydroxy, C 1-6 alkanoyl, and C 1-6 alkoxy; or R 3 and R 4 , together with the nitrogen atom to which R 3 and R 4 are attached, combine to form a 3-7 membered monocyclic heterocyclic group or a 8-11 membered bicyclic heterocyclic group, wherein each group is optionally substituted by one or more substituents selected from halogen, oxo, C 1-6 alkyl, cyano, CF 3 , C 1-6 alkoxy, C 1-6 alkanoyl, aryl and arylC 1-6 alkyl, wherein the aryl and arylC 1-6 alkyl are further optionally substituted by one or more halogen, oxo, C 1-6 alkyl, cyano, CF 3 , C 1-6 alkoxy and C 1-6 alkanoyl; and another active substance selected from the group consisting of a 5HT3 antagonist, a serotonin agonist, an NK-1 antagonist, a selective serotonin reuptake inhibitor, a noradrenaline re-uptake inhibitor, a tricyclic antidepressant, and a dopaminergic antidepressant.